Tempus Announces Multi-Year Collaboration with Moderna and Merck

Tempus announced an expanded multi-year collaboration with Moderna and Merck to support potential commercialization of intismeran autogene (V940/mRNA-4157), a first-in-class individualized neoantigen therapy combined with KEYTRUDA in resected stage IIB-IV melanoma and other cancers. Tempus will manage collection and transfer of tumor tissue and blood samples for next-generation sequencing and, subject to regulatory approvals, provide NGS services supporting the therapy's design and manufacturing.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.